High-yield strains of docosahexaenoic acid (DHA), their construction methods, and applications

By integrating citrate lyase and acetyl-CoA carboxylase genes from *Schizochytrium* or *Saccharomyces cerevisiae* into *Schizochytrium*, the yield and conversion rate of DHA were improved, solving the problem of insufficient DHA production in *Schizochytrium* and achieving efficient and stable DHA production.

CN123107844APending Publication Date: 2026-11-17HEILONGJIANG NHU BIOTECH CO LTD +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611531320.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-30
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing production of docosahexaenoic acid (DHA) by Schizochytrium is insufficient to meet market demand. Traditional sources are affected by seasonal fluctuations and resource depletion, and there is a lack of strains that produce high levels of DHA.

Method used

The gene sequences of citrate lyase and acetyl-CoA carboxylase were integrated into the genome of Schizochytrium and overexpressed. Enzymes derived from Kluyveromyces martensii or Saccharomyces cerevisiae were used to improve DHA production by optimizing the promoter and integration site.

Benefits of technology

It significantly improved the yield and conversion rate of DHA, providing an efficient, stable, and low-cost biomanufacturing platform for the industrial production of DHA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107844A_ABST
    Figure CN123107844A_ABST
Patent Text Reader

Abstract

This invention discloses a high-yield strain of docosahexaenoic acid (DHA), its construction method, and its applications, relating to the field of microbiology. By integrating the encoding genes of citrate lyase and acetyl-CoA carboxylase into a DHA-producing strain, this invention significantly improves DHA yield and conversion rate, providing a novel, efficient, stable, and low-cost biomanufacturing platform for the industrial production of DHA, and possesses high application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of microbiology, and more specifically, to strains that produce high levels of docosahexaenoic acid (DHA), their construction methods, and applications. Background Technology

[0002] Docosahexaenoic acid (DHA, C22:6-) DHA (4,7,10,13,16,19) is an omega-3 long-chain polyunsaturated fatty acid (LC-PUFA). As the main omega-3 fatty acid in brain gray matter, DHA has neurotrophic and neuroprotective effects, which are crucial for normal perinatal cerebral cortical development. Furthermore, DHA supplements can improve human health by enhancing cardioprotective, anti-inflammatory, and anti-cancer activities. Therefore, DHA is widely used as a nutritional supplement, often in the form of nutritional supplements.

[0003] Traditionally, DHA is derived from fish oil extracted from cold-water marine fish. However, seasonal fluctuations, overfishing, and declining populations have hindered a stable supply of DHA to meet the growing market demand. Other commercially available DHA sources are marine microorganisms such as Schizochytrium. Schizochytrium and other Schizochytrium species are excellent DHA producers. Schizochytrium can produce up to 70% of total fatty acids (TFAs) by cell weight, with DHA accounting for 25%-45%. Currently, DHA production by Schizochytrium still needs improvement, and the market lacks strains that can stably produce high levels of DHA.

[0004] In view of this, the present invention is proposed. Summary of the Invention

[0005] The purpose of this invention is to provide strains that produce high levels of docosahexaenoic acid, their construction methods, and applications.

[0006] This invention is implemented as follows: In a first aspect, embodiments of the present invention provide a docosahexaenoic acid (DHA)-producing strain. The preparation method of this strain includes: integrating the gene sequence of a target protein into the genome of a DHA-producing strain, thereby overexpressing the target protein; the target protein includes citrate lyase and acetyl-CoA carboxylase. The target protein is derived from either *Kluyveromyces martensii* or *Saccharomyces cerevisiae*.

[0007] Secondly, embodiments of the present invention provide the application of the docosahexaenoic acid producing strains as described in the foregoing embodiments in the preparation of docosahexaenoic acid or products containing docosahexaenoic acid.

[0008] Thirdly, embodiments of the present invention provide a method for constructing a high-yield docosahexaenoic acid (DHA) strain, comprising: integrating the gene sequence of a target protein into the genome of a DHA-producing strain, thereby overexpressing the target protein; the target protein includes: citrate lyase and / or acetyl-CoA carboxylase. The target protein is derived from either *Kluyveromyces martensii* or *Saccharomyces cerevisiae*.

[0009] The present invention has the following beneficial effects: This invention discovers that by integrating the coding genes for citrate lyase from Kluyveromyces martensii or Saccharomyces cerevisiae and acetyl-CoA carboxylase from Kluyveromyces martensii or Saccharomyces cerevisiae into DHA-producing strains, the yield and conversion rate of DHA are significantly improved. This provides a novel biomanufacturing platform that is efficient, stable, and low-cost for the industrial production of DHA, and has high application value. Attached Figure Description

[0010] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0011] Figure 1The images show gel images of amplified fragments; lane 1: ptub promoter (1194 bp); lane 2: pubi promoter (1229 bp); lane 3: upstream homologous arm of the safe harbor site (1075 bp); lane 4: downstream homologous arm of the safe harbor site (990 bp); lane 5: NOS terminator (224 bp); lane 6: G418 expression cassette (1919 bp); lane 7: plasmid backbone (1903 bp); M: DNA molecular weight marker (250~10000). (Shanghai Sangon Biotech); Lane 8: *Kluyveromyces martensii* citrate lyase gene (1465 bp); Lane 9: *Kluyveromyces martensii* acetyl-CoA carboxylase gene (6739 bp); Lane 10: *Saccharomyces cerevisiae* citrate lyase gene (1423 bp); Lane 11: *Saccharomyces cerevisiae* acetyl-CoA carboxylase gene (6702 bp); Lane 12: *Schizochytrium* citrate lyase gene (1380 bp); Lane 13: *Schizochytrium* acetyl-CoA carboxylase Lane 14: *Yarrowia lipolytica* citrate lyase gene (1953bp); Lane 15: *Yarrowia lipolytica* acetyl-CoA carboxylase gene (6801bp); Lane 16: *Aspergillus nidulans* citrate lyase gene (2013bp); Lane 17: *Aspergillus nidulans* acetyl-CoA carboxylase gene (6867bp); *Pichia pastoris* citrate lyase gene (2019bp); *Pichia pastoris* acetyl-CoA carboxylase gene (6648bp); Figure 2 The DHA potency of each strain; Figure 3 The conversion rate of DHA produced by each strain; Figure 4 Peak diagrams of DHA detection results for CK and JZ-13 by HPLC. Detailed Implementation

[0012] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0013] On one hand, embodiments of the present invention provide a docosahexaenoic acid (DHA)-producing strain. The preparation method of the strain includes: integrating the gene sequence of the target protein into the genome of the DHA-producing strain, thereby overexpressing the target protein; the target protein includes: citrate lyase and acetyl-CoA carboxylase.

[0014] In some embodiments, the integration is site-specific integration to a location 3.2 kb upstream of Schizochytrium cytochrome c.

[0015] In some embodiments, the citrate lyase is derived from any one of Kluyveromyces martensii, Saccharomyces cerevisiae, Yersinia lipolytica, Aspergillus nidulans, Pichia pastoris, and Schizochytrium.

[0016] In some embodiments, the overexpression of the citrate lyase gene is controlled using a ptub promoter or a ppubi promoter. The nucleotide sequence of the ptub promoter is shown in SEQ ID NO:11. The nucleotide sequence of the ppubi promoter is shown in SEQ ID NO:12.

[0017] In some embodiments, the gene sequence of the citrate lyase is shown in any one of SEQ ID NO:2, 6, 9, 14, 18 or 22.

[0018] In some embodiments, the acetyl-CoA carboxylase is derived from any one of Kluyveromyces marxifolia, Saccharomyces cerevisiae, Yersinia lipolytica, Aspergillus nidulans, Pichia pastoris, and Schizochytrium.

[0019] In some embodiments, the gene sequence of the acetyl-CoA carboxylase is shown in any one of SEQ ID NO:4, 8, 10, 16, 20 or 24.

[0020] In some embodiments, the overexpression of the acetyl-CoA carboxylase gene is controlled using a ppubi promoter or a ptub promoter. The nucleotide sequence of the ptub promoter is shown in SEQ ID NO:11. The nucleotide sequence of the ppubi promoter is shown in SEQ ID NO:12.

[0021] In some embodiments, the strain producing docosahexaenoic acid is *Schizochytrium* (…). Schizochytrium sp. ).

[0022] On the other hand, embodiments of the present invention provide the application of the docosahexaenoic acid producing strains as described in any of the foregoing embodiments in the preparation of docosahexaenoic acid or products containing docosahexaenoic acid.

[0023] In some embodiments, the preparation step includes: culturing the docosahexaenoic acid producing strain described in any of the foregoing embodiments.

[0024] In some embodiments, the culture medium used for the culture includes: 45-65 g / L glucose monohydrate, 20-40 g / L monosodium glutamate, 1-20 g / L yeast extract, 1-10 g / L potassium dihydrogen phosphate, 1-10 g / L magnesium sulfate heptahydrate, 1-10 g / L sodium chloride, 0.05-3 g / L calcium chloride, 1-10 g / L anhydrous sodium sulfate, 0.05-1 g / L sodium bicarbonate, 0.1-5 g / L ammonium sulfate, and 0.1-5 g / L potassium chloride.

[0025] In some embodiments, the culture medium used for the culture includes: 50-60 g / L glucose monohydrate, 25-35 g / L monosodium glutamate, 6-12 g / L yeast extract, 1-5 g / L potassium dihydrogen phosphate, 2-8 g / L magnesium sulfate heptahydrate, 1-5 g / L sodium chloride, 0.1-0.5 g / L calcium chloride, 2-6 g / L anhydrous sodium sulfate, 0.1-0.3 g / L sodium bicarbonate, 0.5-3 g / L ammonium sulfate, and 0.5-3 g / L potassium chloride.

[0026] In some embodiments, the pH of the culture medium used for the culture is any one or any two of 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0.

[0027] In some embodiments, the culture conditions include a temperature of 10–40°C and a time of 60–240 h. The temperature can be any one or a range between any two of the following: 10, 12, 14, 16, 18, 20, 22, 24, 26, 27, 28, 29, 30, 32, 34, 36, 38, and 40°C. The time can be any one of the following or a range between any two: 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, and 240h.

[0028] In some embodiments, the cultivation step further includes adding nutrient supplements during the cultivation process.

[0029] In some embodiments, the nutritional supplement includes glucose. For example, each supplement consists of 1 to 20 mL of a glucose solution with a concentration of 10% to 60% (w / v), specifically within any one or any combination of 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 52%, 54%, 55%, 56%, 58%, and 60%.

[0030] In some embodiments, the time points for glucose supplementation include: 15-17 hours, 19-21 hours, 23-25 ​​hours, 39-41 hours, 43-45 hours, 47-49 hours, 63-65 hours, 67-69 hours, and 71-73 hours after the start of fermentation.

[0031] In some embodiments, the strain is activated prior to culturing.

[0032] Furthermore, embodiments of the present invention provide a method for constructing a high-yield docosahexaenoic acid (DHA) strain, comprising: integrating the gene sequence of a target protein into the genome of a DHA-producing strain; wherein the target protein comprises: citrate lyase and / or acetyl-CoA carboxylase.

[0033] In optional embodiments, the construction method is the same as the preparation method of the docosahexaenoic acid producing strain described in any of the foregoing embodiments, and will not be repeated here.

[0034] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0035] The pTargetF plasmid used in the examples was from laboratory stock and its sequence was confirmed by sequencing to be identical to plasmid number #62226 in addgene.

[0036] The pCAMBIA2301 plasmid used in the examples was purchased from Qingke Biotechnology, catalog number: Miaoling P0472.

[0037] The originating strain of *Schizochytrium* in the examples is *Schizochytrium* ( Schizochytrium limacinum ZD-NHU-11, classified as *Schizochytrium limacinum*, was deposited on October 28, 2024, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 41559 and address at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. It has been published in patent number CN120118752A.

[0038] All gene synthesis in this example was provided by Qingke Biotechnology. The reference genomes are: *Kluyveromyces marxianus* DMKU3-1042; *Saccharomyces cerevisiae* S288C; *Yarrowia lipolytica* PO1f; *Aspergillus nidulans* FGSC A4; and *Komagataella phaffii* GS115. The reference genome for codon optimization of all genes is *Schizochytrium sp. ATCC 20888*.

[0039] In this example, high performance liquid chromatography was used to detect the DHA content.

[0040] Solution preparation. Preparation of 1 mg / mL DHA triglyceride standard: Dissolve 100 mg of DHA triglyceride from the standard vial in a small amount of n-hexane, then transfer the entire solution to a 100 mL volumetric flask. Wash and transfer the solution repeatedly with n-hexane to ensure complete transfer. Dilute to the mark with n-hexane. Preparation of 4 mol / L KOH-methanol solution: Weigh 22.4 g of KOH into a 100 mL beaker, add an appropriate amount of anhydrous methanol until the KOH is completely dissolved, cool to room temperature, transfer to a 100 mL volumetric flask, and dilute to the mark with anhydrous methanol. Shake well.

[0041] Standard calibration. Take 2 mL of 1 mg / mL DHA triglyceride standard into a 10 mL centrifuge tube, then add 0.2 mL of 4 mol / L KOH-methanol solution, shake vigorously for 1 min, let stand for 10 min until methyl esterification is complete, and take the supernatant and filter it through a 0.22 μm filter membrane into the liquid phase.

[0042] Sample testing.

[0043] Extraction: Accurately weigh 3 mL of fermentation broth into a 50 mL stoppered test tube, add 6 mL of 6 mol / L hydrochloric acid, mix thoroughly, and then heat in a boiling water bath for 30 min to completely break down the cell walls, shaking once every 5 min during this process. After cooling, first add 10 mL of n-hexane and shake well, then add 10 mL of anhydrous methanol and shake well. Heat in a water bath at 50 °C for 30 min, shaking once every 5 min. After removal, let stand for 10 min to separate the layers.

[0044] Dilution: Dilute the sample 100 times.

[0045] Esterification: Take 2 mL of the diluted solution into a 10 mL centrifuge tube, add 0.2 mL of 4 mol / L KOH-methanol solution, shake vigorously for 1 min, let stand for 10 min until methyl esterification is complete, take the supernatant and filter it through a 0.22 μm filter membrane into the liquid phase.

[0046] Chromatographic conditions. Column: Proshell 120 EC-C18 4μm 150mm 4.6 mm; Mobile phase: methanol: 1‰ phosphoric acid aqueous solution = 90:10; Flow rate: 1 mL / min; Injection volume: 5 μL; Column temperature: 30℃; Detection wavelength: 210 nm; Run time: 15 min.

[0047] Results: The peak area of ​​the sample was compared with that of the standard to calculate the DHA content (g / L) in the sample.

[0048] Example 1 I. Culture medium GYS medium: 20 g / L glucose, 20 g / L yeast extract, 15 g / L sea salt; add 200 mg / L antibiotic G418 as needed. For solid medium, add 1.5 g / L agar.

[0049] Shake-flask fermentation medium: 55 g / L glucose monohydrate, 30 g / L monosodium glutamate, 9 g / L yeast extract, 2.1 g / L potassium dihydrogen phosphate, 5 g / L magnesium sulfate heptahydrate, 2.2 g / L sodium chloride, 0.24 g / L calcium chloride, 4.4 g / L anhydrous sodium sulfate, 0.13 g / L sodium bicarbonate, 1 g / L ammonium sulfate, 0.8 g / L potassium chloride. Adjust pH to 6.0, dissolve glucose, and sterilize separately at 121°C for 30 minutes. After sterilization, combine the flasks and fill 40 mL of the solution into 250 mL shake flasks with baffles.

[0050] II. Construction of Engineered Strains 2.1 Gene Synthesis The gene for *Kluyveromyces martensii* citrate lyase is shown in SEQ ID NO:1, and the optimized codon is shown in SEQ ID NO:2.

[0051] The gene sequence of *Kluyveromyces martensii* acetyl-CoA carboxylase is shown in SEQ ID NO:3, and the optimized codon sequence is shown in SEQ ID NO:4.

[0052] The gene for sacchariformis citrate lyase is shown in SEQ ID NO:5, and the optimized codon is shown in SEQ ID NO:6.

[0053] The gene sequence of acetyl-CoA carboxylase in Saccharomyces cerevisiae is shown in SEQ ID NO:7, and the optimized codon sequence is shown in SEQ ID NO:8.

[0054] The endogenous citrate lyase gene of Schizochytrium is shown in SEQ ID NO:9, and the endogenous acetyl-CoA carboxylase gene is shown in SEQ ID NO:10.

[0055] The gene for citrate lyase in Yersinia lipophila is shown in SEQ ID NO:13, and the optimized codon is shown in SEQ ID NO:14.

[0056] The gene sequence of acetyl-CoA carboxylase in Yersinia lipolytica is shown in SEQ ID NO:15, and the optimized codon sequence is shown in SEQ ID NO:16.

[0057] The citrate lyase gene of Aspergillus nidulans is shown in SEQ ID NO:17, and the optimized codon is shown in SEQ ID NO:18.

[0058] The gene sequence of Aspergillus nidulans acetyl-CoA carboxylase is shown in SEQ ID NO:19, and the optimized codon is shown in SEQ ID NO:20.

[0059] The Pichia pastoris citrate lyase gene is shown in SEQ ID NO:21, and the optimized codon is shown in SEQ ID NO:22.

[0060] The gene sequence of Pichia pastoris acetyl-CoA carboxylase is shown in SEQ ID NO:23, and the optimized codon is shown in SEQ ID NO:24.

[0061] 2.2 Plasmid Construction The overexpressed genes and G418 resistance selection tags were first constructed onto the plasmid, as follows.

[0062] 2.2.1 Single gene overexpression plasmid ZL-01: Using the genome of the originating strain *Schizochytrium* as a template, the first 1000 bp of the ORF frame of tubulin was selected as the ptub promoter sequence, and the ptub promoter fragment (SEQ ID) was amplified using ZLYW-001 / ZLYW-002. NO:11); using the codon-optimized *Kluyveromyces martensii* citrate lyase as a template, the *Kluyveromyces martensii* citrate lyase gene fragment was amplified using ZLYW-003 / 004; using pCAMBIA2301 plasmid as a template, the NOS terminator fragment was amplified using ZLYW-005 / 006; using pCAMBIA2301 plasmid as a template, the G418 resistance gene expression frame fragment was amplified using ZLYW-007 / 008; using the *Schizochytrium* originating strain genome as a template, a 1052bp upstream homologous arm was amplified using ZLYW-UP-F / R; using the *Schizochytrium* originating strain genome as a template, a 970bp downstream homologous arm was amplified using ZLYW-DN-F / R; using pTargetF plasmid as a template, the plasmid backbone fragment was amplified using ZLYW-009 / 010. All PCR amplification products were detected by nucleic acid electrophoresis.

[0063] After purifying and recovering the verified fragments, the ptub promoter, target gene (Kluyveromyces martensii citrate lyase gene fragment), NOS terminator, G418 resistance gene expression cassette, and homologous arms were assembled into a backbone using a ready-to-use seamless cloning kit (Sangon Biotech Order NO. B632219). This was then transformed into *E. coli* Top10 competent cells. After single-cell growth, the transformants were verified using L4440 / SmR-R primers, and the PCR products were sent to Qingke Biotechnology for sequencing to confirm sequence integrity. Finally, plasmid ZL-01 (Kluyveromyces martensii citrate lyase) containing both the target gene expression cassette and the resistance gene expression cassette was obtained.

[0064] 2.2.2 Single gene overexpression plasmids ZL-02~ZL-12 Using the same method as in 2.2.1, the following sequence plasmids were constructed: ZL-02 (Kluyveromyces max-Kluyveromyces acetyl-CoA carboxylase), ZL-03 (Saccharomyces cerevisiae citrate lyase), ZL-04 (Saccharomyces cerevisiae acetyl-CoA carboxylase), ZL-05 (Schizochytrium citrate lyase), ZL-06 (Schizochytrium acetyl-CoA carboxylase), ZL-07 (Yersinia lipolytica citrate lyase), ZL-08 (Yersinia lipolytica acetyl-CoA carboxylase), ZL-09 (Aspergillus nidulans citrate lyase), ZL-10 (Aspergillus nidulans acetyl-CoA carboxylase), ZL-11 (Pichia pastoris citrate lyase), and ZL-12 (Pichia pastoris acetyl-CoA carboxylase).

[0065] Electrophoresis gel images of the fragments amplified during plasmid construction are shown below. Figure 1 . Figure 1 The sizes of each amplified fragment are shown, including those from the ptub promoter, ppubi promoter, citrate lyase from various sources, and acetyl-CoA carboxylase genes. The results show that the sizes of all fragments are consistent with expectations, indicating successful amplification of the target fragments.

[0066] 2.2.3 Combinatorial overexpression plasmid ZL-13: Using the genome of the *Schizochytrium* originating strain as a template, the first 1000 bp of the ubiquitin gene ORF frame was selected as the *pubi* promoter sequence, and the *pubi* promoter fragment (SEQ ID NO: 12) was amplified using ZLYW-033 / ZLYW-034. Using the codon-optimized *Saccharomyces cerevisiae* acetyl-CoA carboxylase gene as a template, the *Saccharomyces cerevisiae* acetyl-CoA carboxylase gene fragment was amplified using ZLYW-035 / ZLYW-036; the *ptub* promoter fragment (SEQ ID NO: 12) was amplified using ZLYW-001 / ZLYW-002. NO:11); using the codon-optimized Kluyveromyces Marcioni citrate lyase as a template, the Kluyveromyces Marcioni citrate lyase gene fragment was amplified using ZLYW-003 / 004; using pCAMBIA2301 plasmid as a template, the NOS terminator fragment was amplified using ZLYW-005 / 006; using pCAMBIA2301 plasmid as a template, the G418 resistance gene expression frame fragment was amplified using ZLYW-007 / 008; using the Schizochytrium originating strain genome as a template, the upstream homologous arm was amplified using ZLYW-UP-F / R; using the Schizochytrium originating strain genome as a template, the downstream homologous arm was amplified using ZLYW-DN-F / R; using pTarget plasmid as a template, the plasmid backbone fragment was amplified using ZLYW-009 / 010.

[0067] After purification, the above fragments were assembled into the pTargetF backbone using a ready-to-use seamless cloning kit (Sangon Biotech Order NO. B632219). This kit included the ppubi promoter, *Saccharomyces cerevisiae* acetyl-CoA carboxylase gene, ptub promoter, *Kluyveromyces martensii* citrate lyase gene, NOS terminator, G418 resistance gene expression cassette, and homologous arms. The resulting fragments were then transformed into *E. coli* Top10 competent cells. After single-cell growth, the transformants were verified using L4440 / SmR-R primers, and the PCR products were sent to Qingke Biotechnology for sequencing to confirm sequence integrity. The final result was plasmid ZL-13, expressing the *Kluyveromyces martensii* citrate lyase gene (ptub), the *Saccharomyces cerevisiae* acetyl-CoA carboxylase gene (pubi), and the resistance expression cassette.

[0068] 2.2.3 Combinatorial overexpression plasmid ZL-14: Using the same method as in 2.2.2, plasmid ZL-14 was constructed, which contains the expression gene of Schizochytrium citrate lyase (ptub) and Schizochytrium acetyl-CoA carboxylase (pubi) as well as the G418 resistance expression frame.

[0069] 2.3 Construction of engineered strains of Schizochytrium 2.3.1 Preparation of electrocompetent cells from the starting strain of Schizochytrium Glycerol tubes containing the *Schizochytrium* strain were removed from a -80°C freezer and streaked onto GYS plates (incubated statically at 28°C for 36 hours) to obtain single colonies. Single colonies were picked and transferred to GYS liquid medium and cultured at 28°C and 220 rpm for 16 hours. The culture was then transferred to a fresh 50 mL GYS liquid medium (initial OD after transfer). 600 In a medium containing 0.1 g / L, incubate at 28°C and 220 rpm until OD reaches 0.1%. 600 The concentration was approximately 0.5. The bacterial cells were centrifuged to collect the precipitate, the supernatant was discarded, and 5 mL of 15 g / L sea salt was added to resuspend the precipitate. The cells were then centrifuged and washed twice. After washing, 5 mL of 1.5% snailase (w / V, Sangon Biotech Order NO. A600870) solution was added to the bacterial cells, and the mixture was gently vortexed to mix. The cells were incubated at 28°C with shaking at 90 rpm for 1 h to disrupt the cell wall. After disruption, the precipitate was collected by centrifugation, washed once with 5 mL of 15 g / L sea salt, and once with 5 mL of 1 mol / L sorbitol. The protoplasts were resuspended in 1 mL of 1 mol / L sorbitol, aliquoted into 100 μL tubes, and stored on ice for later use.

[0070] 2.3.2 Preparation of Electrospinning Fragments Using the plasmids (ZL01, ZL02, ZL03, ZL04, ZL05, ZL06, ZL07, ZL08, ZL09, ZL10, ZL11, ZL12) constructed above as PCR templates, the plasmids were amplified using electroporation fragment amplification primers DZPD-F / DZPD-R to obtain electroporated linear fragments of *Kluyveromyces martensii* citrate lyase, *Kluyveromyces martensii* acetyl-CoA carboxylase, *Saccharomyces cerevisiae* citrate lyase, *Saccharomyces cerevisiae* acetyl-CoA carboxylase, *Schizochytrium* citrate lyase, *Schizochytrium* acetyl-CoA carboxylase, *Yersinia lipolytica* citrate lyase, *Yersinia lipolytica* acetyl-CoA carboxylase, *Aspergillus nidulans* citrate lyase, *Aspergillus nidulans* acetyl-CoA carboxylase, *Pichia pastoris* citrate lyase, and *Pichia pastoris* acetyl-CoA carboxylase.

[0071] Using plasmids ZL13 and ZL14 as PCR templates, electroporation fragment amplification primers DZPD-F / DZPD-R were used to amplify the fragments, obtaining electroporation linear fragments that simultaneously overexpress *Kluyveromyces martensii* citrate lyase (ptub promoter) and *Saccharomyces cerevisiae* acetyl-CoA carboxylase (pubi promoter), as well as electroporation linear fragments that simultaneously overexpress *Schizochytrium* citrate lyase (ptub promoter) and *Schizochytrium* acetyl-CoA carboxylase (pubi promoter).

[0072] 2.3.3 Electroporation Method 5 μg of each of the 14 electroporation linear fragments obtained in step 2.3.2 was added to 100 μL of *Schizochytrium* starting cells for electroporation. After gentle mixing, the mixture was incubated on ice for 5 minutes before electroporation. Electroporation parameters: 1500 V, 4.5 ms, 2 mm electroporation cuvette. Immediately after electroporation, 1 mL of GYS liquid medium was added, and the mixture was incubated at 28°C and 220 rpm for 16 h. The bacterial culture was then spread onto GYS plates containing G418 resistance and incubated at 28°C and 220 rpm for 4–5 days until transformants appeared.

[0073] 2.3.4 Transformer Validation Select the grown single-clonal transformants and use YZYW-F / YZYW-R primers to verify whether the electroporation fragment has been successfully integrated into Schizochytrium. Schizochytrium limacinum The genome of ZD-NHU-11 was sequenced 3.2 kb upstream of cytochrome c, and the sequence integrity was confirmed. Correct transformants were streaked for three consecutive generations, and the genetic stability of the target gene was verified using primers in each generation. Finally, engineered strains JZ-01 (overexpressing the *Kluyveromyces martensii* citrate lyase gene), JZ-02 (overexpressing the *Kluyveromyces martensii* acetyl-CoA carboxylase gene), JZ-03 (overexpressing the *Saccharomyces cerevisiae* citrate lyase gene), and JZ-04 were obtained. JZ-05 (overexpression of Saccharomyces cerevisiae acetyl-CoA carboxylase gene), JZ-06 (overexpression of Schizochytrium acetyl-CoA carboxylase gene), JZ-07 (overexpression of Yersinia lipolytica acetyl-CoA carboxylase gene), JZ-08 (overexpression of Yersinia lipolytica acetyl-CoA carboxylase gene), JZ-09 (overexpression of Aspergillus nidulans citrate lyase gene), JZ-10 (overexpression of Aspergillus nidulans acetyl-CoA carboxylase gene), JZ-11 (overexpression of Pichia pastoris citrate lyase gene), JZ-12 (overexpression of Pichia pastoris acetyl-CoA carboxylase gene), JZ-13 (overexpression of Kluyveromyces marxifolia citrate lyase gene and Saccharomyces cerevisiae acetyl-CoA carboxylase gene), JZ-14 (overexpression of Schizochytrium acetyl-CoA carboxylase gene and Schizochytrium acetyl-CoA carboxylase gene).

[0074] The genetically stable engineered strain was finally obtained, and whole-genome resequencing confirmed that the exogenous gene was integrated in a single copy at 3.2 kb upstream of cytochrome c, with no random integration at other locations.

[0075] The strains are shown in Table 1.

[0076] Table 1 Strains

[0077] III. Shake-flask fermentation The *Schizochytrium* strain preserved in glycerol tubes and the JZ1-14 engineered strain were streaked for activation. Single colonies were picked and transferred to GYS medium and cultured at 28°C and 220 rpm for 24 h. A 5% inoculum was then added to shake-flask fermentation medium, and fermented at 28°C and 170 rpm for 120 h. At fermentation hours 16, 20, 24, 40, 44, 48, 64, 68, and 72, 5 mL of 55% (w / v) glucose solution was added. At the end of fermentation, the DHA potency, percentage, and conversion rate were measured.

[0078] IV. Results Table 2 Results

[0079] Remark: DHA potency (g / L) = Total mass of DHA in fermentation broth (g) / Volume of fermentation broth (L); Conversion rate (%) = Mass of DHA produced (g) / Mass of substrate (g) consumed (g) × 100%.

[0080] The results showed that among the engineered strains that overexpressed citrate lyase and acetyl-CoA carboxylase from different sources, the engineered strain overexpressing citrate lyase from *Kluyveromyces martensii* (JZ-01) exhibited better performance, with a titer of 57.95 g / L and a conversion rate of 16.91%, representing improvements of 7.6% and 7.98% respectively compared to the control. Additionally, the engineered strain overexpressing acetyl-CoA carboxylase from *Saccharomyces cerevisiae* (JZ-04) also contributed to DHA accumulation in cells, achieving a titer of 55.32 g / L and a conversion rate of 16.58%, improvements of 2.72% and 5.87% respectively compared to the control.

[0081] No significant enhancement was observed with citrate lyases and acetyl-CoA carboxylases from other sources. Therefore, citrate lyase from *Kluyveromyces martensii* and acetyl-CoA carboxylase from *Saccharomyces cerevisiae* were co-expressed in *Schizochytrium*. The resulting engineered strain JZ-13 achieved a titer of 60.44 g / L and a conversion rate of 18.3%, representing increases of 12.24% and 17.05% respectively compared to the original *Schizochytrium* strain. Furthermore, compared to JZ-14, which simultaneously overexpressed endogenous citrate lyase and acetyl-CoA carboxylase from *Schizochytrium*, the increases were 9.47% and 13.64% respectively, significantly promoting DHA synthesis in the strain. See details below. Figure 2 and Figure 3 .

[0082] The peak chromatograms of DHA detection results for CK and JZ-13 are shown below. Figure 4 .

[0083] The sequences involved in this application are shown in Table 3.

[0084] Table 3 Sequence

[0085] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A strain for producing docosahexaenoic acid, characterized in that, The method for preparing this strain includes: integrating the gene sequence of the target protein into the genome of a strain that produces docosahexaenoic acid, thereby overexpressing the target protein; the target protein includes: citrate lyase and acetyl-CoA carboxylase; The citrate lyase is derived from either Max Kluyveromyces or Saccharomyces cerevisiae. The acetyl-CoA carboxylase is derived from either Max Kluyveromycetes or Saccharomyces cerevisiae.

2. The docosahexaenoic acid producing strain according to claim 1, characterized in that, The gene sequence of the citrate lyase is shown in SEQ ID NO:

2.

3. The docosahexaenoic acid producing strain according to claim 1, characterized in that, The gene sequence of the acetyl-CoA carboxylase is shown in SEQ ID NO:

8.

4. The docosahexaenoic acid producing strain according to claim 1, characterized in that, The overexpression of the citrate lyase gene is controlled using the ptub or ppubi promoter; And / or, the overexpression of the acetyl-CoA carboxylase gene is controlled using a ppubi promoter or a ptub promoter; The nucleotide sequence of the ptub promoter is shown in SEQ ID NO:11, and the nucleotide sequence of the ppubi promoter is shown in SEQ ID NO:

12.

5. The docosahexaenoic acid producing strain according to any one of claims 1 to 4, characterized in that, The strain producing docosahexaenoic acid is *Schizochytrium* (…). Schizochytrium sp. ).

6. The use of the docosahexaenoic acid producing strain according to any one of claims 1 to 5 in the preparation of docosahexaenoic acid or products containing docosahexaenoic acid.

7. The application according to claim 6, characterized in that, The preparation includes culturing the docosahexaenoic acid producing strain; The cultivation conditions include a temperature of 10~40℃ and a time of 60~240h.

8. A method for constructing a high-yield docosahexaenoic acid strain, characterized in that, It includes: The gene sequence of the target protein is integrated into the genome of a strain that produces docosahexaenoic acid, thereby causing the target protein to be overexpressed. The target protein includes: citrate lyase and / or acetyl-CoA carboxylase; The citrate lyase is derived from either Max Kluyveromyces or Saccharomyces cerevisiae. The acetyl-CoA carboxylase is derived from either Max Kluyveromycetes or Saccharomyces cerevisiae.

9. The construction method according to claim 8, characterized in that, The gene sequence of the citrate lyase is shown in SEQ ID NO:

2.

10. The construction method according to claim 8 or 9, characterized in that, The gene sequence of the acetyl-CoA carboxylase is shown in SEQ ID NO:8.

Citation Information

Patent Citations

  • DHA (docosahexaenoic acid) production strain and application thereof

    CN120118752A